Abstract-In this study, we investigated the feasibility of using 3.5-Fr IVUS catheters for minimally-invasive, image-guided hyperthermia treatment of tumors in the brain. Feasibility is demonstrated in two ways: 1) by fitting a 3.5-Fr IVUS catheter with a 5 × 0.5 × 0.22 mm PZT-4 transducer for 9-MHz imaging, and 2) by testing an identical transducer for therapy potential with 3.3-MHz CW excitation. The imaging transducer's performance was compared to a 9-Fr, 9-MHz ICE catheter as a gold standard, visualizing a 2.5-cm cyst phantom and a postmortem ovine brain. The therapy transducer was able to maintain a power output of 700 mW, achieving a temperature rise of +19°C at a depth of 1.5 mm in excised brain tumor tissue.
INTRODUCTION
The long-term goal of this research is the development of a minimally-invasive, endovascular approach to administering localized, image-guided ultrasound hyperthermia in the brain, providing targeted control of drug release from thermosensitive liposomes and opening the blood-brain barrier, which would enhance chemotherapeutic efficacy for malignant brain tumor treatment. The design goal is a dual-mode ultrasound catheter that is both thin and flexible enough to navigate a vascular pathway to the brain and be placed immediately adjacent to a brain tumor target, to visualize the tumor and then direct an ultrasound hyperthermia beam to trigger the release of drugs contained within thermosensitive liposomes molecularly targeted to regions of tumor angiogenesis (see Figure 1 ). Previously we used 10-and 12-Fr phased-array catheter probes to image an in vivo canine brain (see Figure 2) , and we evaluated various IVUS transducer apertures using a thermal model [1] . Here we investigate the merit of using a dualfrequency PZT-4 transducer by fabricating and testing imaging and tissue-heating prototypes.
A. Clinical Motivation
In 2009, an estimated 13,000 people in the U.S. died from a primary malignant brain and central nervous system (CNS) tumor, with over 22,000 new cases diagnosed [2] . Malignant gliomas account for 81% of all malignant primary brain/CNS tumors, and 51% of gliomas are of the WHO grade IV subtype glioblastoma multiforme (GBM), the most common intracranial neoplasm [3, 4] . Currently, primary brain tumors are most commonly treated by surgery, radiotherapy, and chemotherapy [5] . Chemotherapy may be administered systemically, by mouth or intravenous infusion, or locally, by direct intra-arterial or interstitial injection [6] . The major challenge to effectively treating CNS tumors is achieving high drug concentration within the tumor bed [7] .
B. Thermosensitive Liposomes & Hyperthermia
Liposomes are membrane-enclosed vesicles composed of a lipid bilayer shell (which can trap hydrophobic and amphipathic drugs) surrounding an aqueous core (which can (a) (b)
contain hydrophilic drugs), with a diameter typically around 100 nm [8] . Liposomes can be readily conjugated to antibodies or other adhesion ligands such as integrin α v β 3 (found to be overly expressed in regions of tumor angiogenesis) to enable active targeting of a tumor site [9] . Thermosensitive liposomes containing the cancer drug doxorubicin have been shown to quickly release their contents when the surrounding temperature is raised to 41°C (4°C above normal body temperature) [10] . Therefore, thermosensitive liposomes, in combination with local hyperthermia-which may be created and directed by ultrasound-can provide targeted control of drug release that may augment chemotherapeutic efficacy in many clinical settings [10, 11] .
C. IVUS Catheters
Intravascular ultrasound (IVUS) imaging was developed to provide high-quality tomographic visualization of the coronary vessels in vivo [12, 13] . Because coronary arteries typically have a lumen diameter on the order of 2-3 mm and layers of the arterial wall may be less than 300 μm thick, mechanical IVUS catheters commonly use a single rotating piezoelectric crystal (20-40 MHz with less than 3 mm 2 surface area) within a sheath that's typically less than 4 Fr [13] [14] [15] . Commercially-available IVUS catheters have an appropriate form factor-are both thin and flexible enough-to achieve the desired placement within the brain volume via our intended vascular approach, so they are considered here as one possible platform for a dual-mode intracranial catheter integrating ultrasound imaging and hyperthermia.
II. METHODS
For our prototypes, PZT-4 was used because its properties (high k T and Q m , low tan δ) make it an excellent choice of material for dual-mode imaging and therapy transducers. A 9-MHz resonance for imaging corresponds to a PZT-4 thickness of 0.22 mm, and the maximum-allowable aperture geometry for a flexible 3.5-Fr IVUS catheter was determined to be 5 × 0.5 mm. Consequently, two prototypes were built using 5 × 0.5 × 0.22 mm PZT-4: one to assess imaging performance in a mechanical IVUS catheter, and one to assess therapeutic potential by hyperthermia generation.
A. Imaging Prototype
The 9-MHz PZT-4 transducer was used to replace the 40-MHz element in a Boston Scientific (Natick, MA, USA) Atlantis TM SR Pro coronary imaging catheter. The metal housing at the tip was filed down to create a shelf where the longer 9-MHz transducer was bonded with silver epoxy (CHO-BOND, Chomerics, Woburn, MA, USA). The front contact was connected to the signal wire-protruding from the middle of the housing-with silver epoxy, and a coating of 20-minute epoxy (Finish-Cure, Bob Smith Industries, Atascadero, CA, USA) was applied as reinforcement. Finally, to ensure that sound was transmitted and received only through the front face of the transducer, an improvised air backing was created using a mixture of 20-minute epoxy and phenolic microballoons (BJO-0930, Asia Pacific Microballoons, Selangor, Malaysia). A schematic of the prototype is shown in Figure 3 . To assess imaging performance, the modified Atlantis IVUS prototype was compared to a Boston Scientific 9-Fr intracardiac echo (ICE) catheter (Ultra ICE TM ; see Figure 4a ) as a gold standard for 9-MHz imaging with a ClearView Ultra TM scanner. Each catheter was used to image two targets: a 2.5-cm-diameter cyst phantom, and a post-mortem ovine brain. To image the ovine brain 30 minutes post-mortem, a burr hole was made along the midline of the skull, angled posteriorly. This allowed catheter insertion into the superior sagittal sinus, such that the imaging plane (perpendicular to the catheter axis) could be swept over the brain volume (see Figure 5 ). 
B. Therapeutic Prototype
A high-power prototype was constructed using a piece of PZT-4 identical to that used in the 9-MHz imaging prototype. Double-sided metallized liquid crystal polymer (LCP, 20 μm thick) was bonded to the face of the ceramic with silver epoxy, to provide both a signal ground contact and a separate outer ground layer to shield RF noise. A 4-ft coaxial cable was removed from inside an Atlantis catheter, and its ground and signal wires exposed; these were bonded to the front and back contacts of the PZT-4, respectively. An epoxy-andmicroballoons air backing was applied (similar to the imaging prototype), and the transducer was secured and sealed in a 9-Fr catheter scrap, in side-viewing configuration. After measuring the electrical impedance of the prototype and a 25-W RF power amplifier (Model 525LA, ENI, Rochester, NY, USA), a matching circuit was designed and built to maximize power transfer at 3.3 MHz.
To assess therapeutic potential, the transducer was placed in contact with an excised glioblastoma tumor which had been grown artificially on the flank of a nude mouse. A type T, 33-gauge, hypodermic needle thermocouple (HYP-0, Omega Engineering, Stamford, CT, USA) was inserted approximately 1.5 mm beneath the surface of the tissue and aligned with the center of the transducer to measure the tissue temperature. A waveform generator (Model 33250, Agilent, Santa Clara, CA, USA) was connected to the power amplifier to produce continuous-wave (CW) excitation at 3.3 MHz. The power was alternately turned on and off for 90 seconds at a time, at levels of 700, 350, and 175 mW.
III. RESULTS

A. Imaging
The modified IVUS prototype transducer is shown in Figure 4c . Figures 4b and 4d are 9-MHz images of a 2.5-cm cyst phantom acquired by the commercial 9-Fr ICE catheter and the 3.5-Fr modified IVUS prototype. Though the goldstandard ICE catheter outperforms the prototype in terms of lateral resolution and sensitivity, the images are comparable. Additionally, we have preliminary results from an in vivo porcine model, where the 3.5-Fr modified IVUS prototype successfully obtained images in the right vertebral artery (see Figure 7 ). 
B. Therapy
The high-power, 3.3-MHz prototype transducer was able to achieve significant levels of hyperthermia in excised brain tumor tissue. In 90 seconds of CW excitation at 700 mW, a temperature rise of 19.1°C was measured. Subsequently, temperature rises of 9.2°C and 4.9°C were created using 350 mW and 175 mW of CW power, respectively (see Figure 8 ). 
IV. DISCUSSION
A 5 × 0.5 × 0.22 mm PZT-4 transducer was used to build a 9-MHz imaging prototype in a 3.5-Fr mechanical IVUS catheter, and a 3.3-MHz high-power prototype for therapy. The imaging prototype performed comparably to a 9-Fr commercial ICE catheter in identifying anatomical structures in an ovine brain, and the therapy prototype achieved a temperature rise as high as 19.1°C at 1.5 mm deep in excised brain tumor tissuemuch higher than the minimum increase of 4°C necessary for drug release from thermosensitive liposomes. These results indicate that combining these capabilities into a single dualmode device may be feasible, and that this technology could become clinically viable.
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